News

mRNA, CureVac and BioNTech

CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement,
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.
CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.
Pfizer, BioNTech reach Covid jab settlement with GSK, CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 million
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over mRNA vaccine patents. Read more here.
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna’s patents at London’s Court of Appeal.
Covid vaccine patent fight finally ends: Pfizer-BioNTech to pay CureVac and GSK US$740m plus US sales royalties
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac US$740 million plus royalties to
GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation in the US – in the wake of BioNTech's recent agreement to acquire its former rival in a $1.25 billion deal.
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Pfizer's Turnaround Has Truly Started (Earnings Update)
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
Pfizer raises 2025 profit forecast as cost-cutting program gains traction
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Earnings live: Palantir stock pops, Pfizer beats, Caterpillar warns of tariff impact
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
Pfizer rises as Q2 beat leads to guidance raise
Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than ...